| Course | NU 636 Advanced Pharmacology |
|---|---|
| Unit | Unit 7 |
| Paper type | Drug comparison paper |
| Length | About 1,030 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN Family Nurse Practitioner |
| Updated | October 2026 |
Free sample paper for NU 636 Unit 7
Atorvastatin Versus Rosuvastatin When the Kidneys Are at Stage 4: Breaking the Tie for a Man of 68
Student Name
Department of Nursing, Herzing University
NU 636: Advanced Pharmacology
Instructor Name
March 11, 2026
Atorvastatin Versus Rosuvastatin When the Kidneys Are at Stage 4: Breaking the Tie for a Man of 68
The Agents and the Axes
Atorvastatin and rosuvastatin are the two statins most often prescribed when a patient needs a substantial reduction in low-density lipoprotein cholesterol (LDL-C). Both are available as inexpensive generics, both are taken once daily, and both can deliver high-intensity therapy. This paper compares them on six axes: LDL-C lowering, outcome evidence, handling by the kidney, interaction pathways, population-specific exposure, and practical factors of cost and convenience.
These axes were chosen because each one can change which agent a particular patient should receive. Axes on which the two agents are effectively identical, such as the class mechanism of HMG-CoA reductase inhibition, the rare risk of liver enzyme elevation, and the small increase in new-onset diabetes, are set aside because they cannot break a tie. The comparison runs axis by axis, and within each axis atorvastatin is discussed first and rosuvastatin second.
Axis One: LDL-C Lowering
Atorvastatin lowers LDL-C by roughly 30% to 50% across its dose range of 10 to 80 mg, with 40 to 80 mg qualifying as high intensity. Rosuvastatin is more potent per milligram: in the STELLAR trial, rosuvastatin 10 to 40 mg lowered LDL-C by 46% to 55%, compared with 37% to 51% for atorvastatin 10 to 80 mg (Jones et al., 2003). At their maximum doses the difference is several percentage points in favor of rosuvastatin. Verdict: rosuvastatin wins on potency, but the margin matters only when a patient needs the very largest reduction.
Axis Two: Outcome Evidence
Atorvastatin reduced coronary events in patients with hypertension and average cholesterol in the lipid-lowering arm of ASCOT, which was stopped early because of benefit (Sever et al., 2003). Rosuvastatin reduced major cardiovascular events in people with normal LDL-C and elevated high-sensitivity C-reactive protein in JUPITER, also stopped early (Ridker et al., 2008). Both agents have large randomized outcome trials behind them, and neither trial directly compared the two drugs. Verdict: a tie. Neither agent has a stronger class of evidence for general cardiovascular prevention.
Axis Three: Handling by the Kidney
Atorvastatin is cleared mainly by the liver, and less than 2% appears in the urine, so no dose adjustment is required for any level of kidney function. Rosuvastatin is partly cleared by the kidney; in severe kidney impairment not requiring dialysis, its labeling calls for a starting dose of 5 mg and a maximum of 10 mg, because exposure rises substantially as clearance falls. Verdict: atorvastatin wins clearly when kidney function is severely reduced, because it can be used across its full dose range without adjustment.
Axis Four: Interaction Pathways
Atorvastatin is metabolized by cytochrome P450 3A4, so strong inhibitors of that enzyme, including clarithromycin, itraconazole, and some antiretroviral regimens, raise its levels and the risk of myopathy. Rosuvastatin undergoes little cytochrome metabolism, which removes most of those interactions, but it depends on hepatic uptake transporters, so drugs such as cyclosporine and gemfibrozil raise its levels. Verdict: rosuvastatin wins for a patient taking a strong 3A4 inhibitor; atorvastatin wins for a patient on cyclosporine or requiring a fibrate.
Axis Five: Population-Specific Exposure
Plasma exposure to rosuvastatin is about twice as high in people of East Asian ancestry as in White people living in the same environment, a difference not explained by diet or body size (Lee et al., 2005). Its labeling therefore recommends a lower starting dose for Asian patients. No comparable ancestry-related adjustment applies to atorvastatin. Verdict: atorvastatin is simpler to dose in patients of Asian ancestry, though rosuvastatin remains usable at a lower dose.
Axis Six: Cost and Convenience
Both agents are generic and inexpensive on most insurance plans, both are taken once daily at any time of day, and both are well tolerated by most patients. Adherence is the practical issue that matters more than either drug: a statin that is prescribed but not taken prevents nothing, so the choice should favor whichever agent the patient's plan covers with the lowest copay and whichever he is least likely to stop. Verdict: a tie.
The Patient Who Breaks the Tie
Mr. J., a composite 68-year-old man, has chronic kidney disease stage 4 with an estimated glomerular filtration rate of 24 mL/min/1.73 m2, type 2 diabetes, and hypertension. He is not on dialysis. His LDL-C is 142 mg/dL. He takes insulin glargine, amlodipine, furosemide, and sodium bicarbonate, none of which is a strong 3A4 inhibitor or transporter inhibitor. He is of Filipino ancestry. For adults 50 years and older with an eGFR below 60 who are not on dialysis, statin therapy is recommended to reduce cardiovascular risk, and the kidney guideline suggests using doses that were proven in trials in this population rather than pushing to maximum intensity (Wanner & Tonelli, 2014).
For Mr. J., three axes carry the decision. His kidney function makes atorvastatin's lack of renal adjustment decisive. His ancestry adds a second reason to be cautious with rosuvastatin exposure. And the interaction axis does not favor rosuvastatin, because he takes no 3A4 inhibitors. The potency advantage of rosuvastatin is irrelevant, because his target does not require the largest possible reduction and the capped 10 mg dose of rosuvastatin would remove much of that advantage anyway.
Recommendation and What Would Reverse It
Recommendation: atorvastatin 20 mg by mouth once daily, with a lipid panel and creatine kinase only if muscle symptoms arise, and a repeat lipid panel in 6 to 12 weeks to confirm response and adherence.
What would reverse the answer: if Mr. J. needed a long course of a strong 3A4 inhibitor, such as a boosted antiretroviral regimen, rosuvastatin at a reduced dose would become the safer choice. If his kidney function were stable above 30 mL/min/1.73 m2 and he needed a very large LDL-C reduction after an acute coronary event, rosuvastatin's greater potency would matter more. If he began dialysis, the question would change altogether, because statins have not shown benefit when started in patients already on dialysis.
What the losing agent still does better: rosuvastatin delivers more LDL-C reduction per milligram and avoids the long list of 3A4 interactions that shadows atorvastatin in patients with many medications.
References
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). American Journal of Cardiology, 92(2), 152-160. https://doi.org/10.1016/S0002-9149(03)00530-7
Lee, E., Ryan, S., Birmingham, B., Zalikowski, J., March, R., Ambrose, H., Moore, R., Lee, C., Chen, Y., & Schneck, D. (2005). Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clinical Pharmacology & Therapeutics, 78(4), 330-341. https://doi.org/10.1016/j.clpt.2005.06.013
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Jr., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Glynn, R. J. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359(21), 2195-2207. https://doi.org/10.1056/NEJMoa0807646
Sever, P. S., Dahlof, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., O'Brien, E., & Ostergren, J. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. The Lancet, 361(9364), 1149-1158. https://doi.org/10.1016/S0140-6736(03)12948-0
Wanner, C., & Tonelli, M. (2014). KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney International, 85(6), 1303-1309. https://doi.org/10.1038/ki.2014.31
The Herzing NU 636 Unit 7 instructions
Here you set two drugs with the same purpose side by side and recommend one for a particular patient. Expect to set out the axes of comparison in advance, such as efficacy, outcome evidence, pharmacokinetics, interactions, safety in specific populations and cost. Each axis should be covered for both agents with evidence. Many sections want a clear recommendation tied to the patient's characteristics and a statement of what would change it. Landmark trials and current guidelines are the usual sources, referenced in APA 7, at whatever length your rubric gives. Choose agents that are genuinely comparable, since a pairing with an obvious winner leaves little to analyze. Use a composite patient for the final decision and include dosing and monitoring for the drug you recommend.
Inside the NU 636 Unit 7 example
The paper opens by naming the two statins and the six axes it will use, so the reader can follow the structure. LDL lowering is compared across dose ranges with data from a head-to-head trial. Outcome evidence is summarized from trials in different populations for each agent. The kidney axis explains that atorvastatin is cleared mainly by the liver and needs no adjustment, while rosuvastatin is partly cleared by the kidney and is capped at low filtration rates. Interactions are compared by pathway, cytochrome P450 3A4 for atorvastatin and transporter effects for rosuvastatin. Exposure differences by ancestry and cost are covered briefly. The patient section introduces the man with stage 4 kidney disease and shows how the kidney axis decides the case. The recommendation gives a dose, monitoring and reversal conditions.
Where the points sit in the NU 636 Unit 7 rubric
Points in the Herzing rubric for a comparison paper typically go to selection of comparable agents, balanced analysis across criteria, use of evidence, application to the patient and writing. Balance is usually the criterion markers read most closely; full credit requires each axis to be covered for both agents, not detailed coverage of one and a sentence on the other. Evidence points depend on trials and guidelines cited accurately. Application is credited when the recommendation follows from a specific patient factor and includes dose and monitoring. Many rubrics reward naming what would reverse the recommendation, which shows the decision is reasoned rather than preferred. Writing points cover a parallel structure, accurate units and doses, and APA citations, including trial names explained the first time they appear.
NU 636 Unit 7 help before you submit
Comparison papers commonly lose points by describing each drug in its own section, which makes the reader do the comparing. Students also choose a pair where one agent is clearly better, leaving no real analysis. Efficacy is often presented with percentages but no source or dose range. Kidney or liver handling is frequently mentioned without the practical consequence, such as a dose cap. Another common gap is a recommendation that ignores the patient's main characteristic. Trials are sometimes named without explaining who was studied, which limits how far their results apply. Cost is a legitimate axis and is often skipped. Finally, include what would change the recommendation; a decision with no conditions attached reads as preference instead of reasoning.
Get a NU 636 Unit 7 example written to your instructions
Send the Unit 7 instructions and the rubric from your NU 636 classroom, plus the two agents you have been asked to compare and any patient details supplied. We write a custom example against those criteria, with matched axes and a recommendation that commits, and return it in 24 to 48 hours. The first custom sample is free.
More NU 636 papers and FNP samples
- NU 636 Unit 1: Drug class profile
- NU 636 Unit 2: Prescribing rationale
- NU 636 Unit 3: Pharmacotherapy plan
- NU 636 Unit 4: Patient education handout
- NU 636 Unit 5: Drug therapy paper
- NU 636 Unit 6: Discussion post
- NU 636 Unit 8: Comprehensive case study
- NU 631 Unit 7: Safety screening and response protocol
- NU 632 Unit 7: Family-centered chronic condition plan
- NU 610 Unit 7: Case analysis
- NU 611 Unit 7: Diagnostic error analysis
NU 636 Unit 7 questions, answered
How do I pick which two agents to compare?
Take two that a prescriber would realistically weigh against each other for the same indication, which usually means the same class or two classes used interchangeably. If one is obviously first line and the other is rarely used, the comparison writes itself and demonstrates nothing. The best pairs are the ones where practitioners genuinely disagree and the evidence supports both.
Is cost a legitimate axis in a graduate paper?
Yes, and treating it as clinical rather than administrative usually strengthens the work. A drug the patient cannot afford or cannot obtain is a drug that will not be taken, which affects outcomes as directly as any pharmacological property. Argue it that way, with a source where one exists, rather than asserting that one agent is cheaper without evidence for the claim.
Does the paper have to reach a winner?
For a described patient, yes. A comparison that ends by saying the decision depends on individual factors, without ever applying those factors to a person, has stopped one step short of the reasoning being graded. Describe the patient, apply the axes, commit to an agent, then name what would reverse the decision. That last part is where strong versions separate.
Where can I find a free NU 636 Unit 7 sample paper?
You can read the whole NU 636 Unit 7 statin comparison here without charge, all six axes, the patient who breaks the tie and the recommendation. If you are comparing other agents, request a custom paper; it is free and normally delivered within a day or two.
How do I compare two drugs in a NU 636 paper?
Choose agents used for the same purpose, then compare both on the same axes: efficacy, outcome trials, kidney and liver handling, interactions, special populations and cost. Finish with one patient whose characteristics decide between them, a full dose and what would reverse your choice.